CN106188232B - 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法 - Google Patents

肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法 Download PDF

Info

Publication number
CN106188232B
CN106188232B CN201610552695.3A CN201610552695A CN106188232B CN 106188232 B CN106188232 B CN 106188232B CN 201610552695 A CN201610552695 A CN 201610552695A CN 106188232 B CN106188232 B CN 106188232B
Authority
CN
China
Prior art keywords
hours
peptide
ip3r3
minutes
ebin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610552695.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106188232A (zh
Inventor
Y.A.科马罗娃
U.萨基布
S.M.沃格尔
A.B.马利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Illinois Trust Management Committee, University of
Original Assignee
Illinois Trust Management Committee, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Illinois Trust Management Committee, University of filed Critical Illinois Trust Management Committee, University of
Publication of CN106188232A publication Critical patent/CN106188232A/zh
Application granted granted Critical
Publication of CN106188232B publication Critical patent/CN106188232B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201610552695.3A 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法 Active CN106188232B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496409P 2011-06-13 2011-06-13
US61/496,409 2011-06-13
CN201280029277.6A CN103608026B (zh) 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280029277.6A Division CN103608026B (zh) 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Publications (2)

Publication Number Publication Date
CN106188232A CN106188232A (zh) 2016-12-07
CN106188232B true CN106188232B (zh) 2020-01-07

Family

ID=47357694

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610552695.3A Active CN106188232B (zh) 2011-06-13 2012-06-13 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法
CN201280029277.6A Active CN103608026B (zh) 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280029277.6A Active CN103608026B (zh) 2011-06-13 2012-06-13 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Country Status (15)

Country Link
US (2) US9248198B2 (https=)
EP (1) EP2717897B1 (https=)
JP (1) JP6042425B2 (https=)
KR (1) KR102042015B1 (https=)
CN (2) CN106188232B (https=)
AU (1) AU2012271781C1 (https=)
BR (1) BR112013032108B1 (https=)
CA (1) CA2838662C (https=)
DK (1) DK2717897T3 (https=)
ES (1) ES2633343T3 (https=)
IL (1) IL229771B (https=)
MX (1) MX349146B (https=)
PL (1) PL2717897T3 (https=)
WO (1) WO2012174028A2 (https=)
ZA (1) ZA201309161B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
CN110128506B (zh) * 2019-05-22 2021-03-30 中国药科大学 一种寡肽及其应用
CN110664990B (zh) * 2019-11-07 2021-03-16 江南大学 一种trpc1肽类分子在制备治疗病毒感染引起的炎症的药物中的应用
TW202204375A (zh) * 2020-04-15 2022-02-01 美商寇峇有限公司 治療冠狀病毒感染之方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903145A2 (en) * 1997-04-30 1999-03-24 Eli Lilly And Company Pharmaceutical composition for skin disorders
CN1890218A (zh) * 2003-12-03 2007-01-03 西托匹亚研究有限公司 微管蛋白抑制剂
CN103608026B (zh) * 2011-06-13 2016-08-24 伊利诺伊大学受托管理委员会 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US8304382B2 (en) * 2006-07-21 2012-11-06 Cristalia Productos Quimicos Farmaceuticos Ltda. Anti-inflammatory and anti-allergic cyclic peptides
WO2008011621A2 (en) * 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
IT1392567B1 (it) * 2008-12-24 2012-03-09 Bioindustry Park Del Canavese S P A Uso di un peptide derivato da er-alfa per il ripristino della sensibilita' a composti antiestrogenici in cellule di tumore mammario
US20100190691A1 (en) * 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903145A2 (en) * 1997-04-30 1999-03-24 Eli Lilly And Company Pharmaceutical composition for skin disorders
CN1890218A (zh) * 2003-12-03 2007-01-03 西托匹亚研究有限公司 微管蛋白抑制剂
CN103608026B (zh) * 2011-06-13 2016-08-24 伊利诺伊大学受托管理委员会 肽组合物和用于治疗肺损伤、哮喘、过敏反应、血管性水肿、全身性血管通透综合征和鼻塞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Microtubule-associated protein EB3 regulates calcium signaling and facilitates increase in endothelial permeability;Yulia A Komarova等;《The FASEB Journal》;20110430;第25卷;摘要 *

Also Published As

Publication number Publication date
US9248198B2 (en) 2016-02-02
KR20140056185A (ko) 2014-05-09
CN106188232A (zh) 2016-12-07
AU2012271781B2 (en) 2017-02-16
CN103608026A (zh) 2014-02-26
US20140213505A1 (en) 2014-07-31
EP2717897A2 (en) 2014-04-16
CA2838662A1 (en) 2012-12-20
MX349146B (es) 2017-07-14
AU2012271781C1 (en) 2017-09-21
ZA201309161B (en) 2015-03-25
US20140155314A1 (en) 2014-06-05
WO2012174028A3 (en) 2013-02-21
PL2717897T3 (pl) 2017-09-29
WO2012174028A2 (en) 2012-12-20
ES2633343T3 (es) 2017-09-20
JP2014518211A (ja) 2014-07-28
DK2717897T3 (en) 2017-07-17
EP2717897B1 (en) 2017-04-19
AU2012271781A1 (en) 2014-01-09
US8912139B2 (en) 2014-12-16
KR102042015B1 (ko) 2019-11-07
BR112013032108A2 (pt) 2016-11-22
CA2838662C (en) 2018-07-24
CN103608026B (zh) 2016-08-24
MX2013014650A (es) 2014-01-24
BR112013032108B1 (pt) 2021-10-26
JP6042425B2 (ja) 2016-12-14
EP2717897A4 (en) 2015-01-07
IL229771B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
ES2637687T3 (es) Péptido BAD de dominio BH3 para usar en el tratamiento o retardo de la aparición de la diabetes
DK2650008T3 (en) Use of Cell Permeable Peptide Inhibitors by the JNK Signal Transduction Pathway for the Treatment of Various Cancer Diseases
Zhang et al. NRG1-Fc improves metabolic health via dual hepatic and central action
CN106188232B (zh) 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法
KR20210076190A (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
ES2958662T3 (es) Tratamiento de cardiopatía por inhibición de la acción de la proteína de anclaje a la cinasa A del músculo (mAKAP)
Johnstone et al. STIM proteins: integrators of signalling pathways in development, differentiation and disease
EP3160489B9 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
CN111712252A (zh) 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
US10064911B2 (en) Peptides for treating cancer
CN106459168A (zh) 强心性类固醇拮抗剂和相关方法
Wang et al. Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis
CN113874029B (zh) 基于cp2c靶向肽的抗癌剂
Tan et al. Klotho-derived peptide 1 ameliorates hepatic fibrosis induced by αKlotho deficiency and liver injury
US20130345143A1 (en) MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
US10125183B2 (en) Decoy peptides inhibiting binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1
Vannini et al. CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo. Toxins 2021, 13, 194
KR100729210B1 (ko) 내피세포 성장호르몬에 대한 길항작용이 증진된 펩티드 및이로부터 제조되는 치료제
KR101410417B1 (ko) 혈액내의 엔도칸 측정 방법
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
HK1247573B (zh) 用於抑制血管生成的肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant